A systematic review of calciumchannel blocker use and cognitive decline/dementia in the elderly

Journal of Hypertension

Volumn 32, Issue 10, 2014, Pages 1945-1958

  Peters, Ruth ^a   Booth, Andrew ^b   Peters, Jean ^b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Aged; Alzheimer's disease; Calcium channel blockers; Cognitive disorders; Dementia

Indexed keywords

ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT;

ALZHEIMER DISEASE; BLOOD PRESSURE MEASUREMENT; COGNITION; COHORT ANALYSIS; DEMENTIA; DIASTOLIC BLOOD PRESSURE; FOLLOW UP; HUMAN; HYPERTENSION; PRIORITY JOURNAL; PSYCHOLOGIC TEST; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; UNITED STATES; VERY ELDERLY; AGED; COGNITION DISORDERS; COMPLICATION; DRUG UTILIZATION; RISK REDUCTION;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; COGNITION; COGNITION DISORDERS; DEMENTIA; DRUG UTILIZATION; HUMANS; HYPERTENSION; RISK REDUCTION BEHAVIOR;

EID: 84925826912     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0000000000000273     Document Type: Review

References (55)

1. Report on World Population Ageing 1950-2050 United Nations Population Division DESA xxvii-xxxi. http://www.un.org/esa/population/ publications/worldageing19502050/
2. Euser S, Bemmel T, Schram M, Gussekloo J, Hofman A, Westendorp R, Breteler M. The effect of age on the association between blood pressure and cognitive function later in life. JAGS 2009; 57:1223-1237.
3. Kennelly S, Lawlor B, Kenny R. Blood pressure and the risk for dementia-a double edged sword. Ageing Res Rev 2009; 8:61-70.
4. Beckett N, Peters R, Fletcher AE, Staessen J, Liu L, Dumitrascu D, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008; 358:1887-1898.
5. Beckett N, Peters R, Tuomilehto J, Swift C, Sever P, Potter J, et al. Immediate and late benefits of treating very elderly people with hypertension: results from active treatment extension to hypertension in the very elderly randomised controlled trial. BMJ 2012; 344:d7541.
6. Tzourio C, Dufouil C, Ducimetiére P, Alpérovitch A, for the EVA study group. Cognitive decline in individuals with high blood pressure: a longitudinal study in the elderly. Neurology 1999; 53:1948-1952.
7. Skoog I, Lernfelt B, Landahl S, Palmertz B, Andreasson LA, Nilsson L, et al. A 15 year longitudinal study of blood pressure and dementia. Lancet 1996; 347:1141-1145.
8. Launer L, Masaki K, Petrovitch H, Foley D, Havlik R. The association between midlife blood pressure levels and late-life cognitive function. JAMA 1995; 274:1846-1851.
9. Elias M, Wolf P, D'Agostino R, Cobb J, White L. Untreated blood pressure level is inversely related to cognitive functioning: the Framingham study. Am J Epidemiol 1993; 138:353-364.
10. Kilander L, Nyman H, Boberg M, Hansson L, Lithell H. Hypertension is related to cognitive impairment. A 20-year follow-up of 999 men. Hypertension 1998; 31:780-786.
11. Peters R, Beckett N, Forette F, Tuomilehto J, Clarke R, Ritchie C, et al. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo-controlled trial. Lancet Neurol 2008; 7:683-689.
12. Feigin V, Ratnasabapathy Y, Anderson C. Does blood pressure lowering treatment prevent dementia or cognitive decline in patients with cardiovascular and cerebrovascular disease? J Neurol Sci 2005; 229:151-155.
13. McGuiness B, Todd S, Passmore P, Bullok R. Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive decline and dementia. Cochrane Database Syst Rev 2009; CD004034.
14. Shah K, Qureshi S, Johnson M, Parikh N, Schulz P, Kunik M. Does use of antihypertensive drugs affect the incidence or progression of dementia? A systematic review. Am J Geriatr Pharmacother 2009; 7:v250-v261.
15. Fournier A, Oprisiu-Fournier R, Serot J, Godefroy O, Achard J, Faure S, et al. Prevention of dementia by antihypertensive drugs: how AT1-receptor-blockers and dihydropyridines better prevent dementia in hypertensive patients than thiazides and ACE-inhibitors. Expert Rev Neurother 2009; 9:1413-1431.
16. Forette F, Seux M, Staessen J, Thijs L, Birkenhäger W, Babarskiene MR, et al. Prevention of dementia in a randomised double-blind placebocontrolled systolic hypertension in Europe (SYST-EUR) trial. Lancet 1998; 352:1347-1351.
17. Forette F, Seux M, Staessen J, Thijs L, Babarskiene M, Babeanu S, et al. Systolic hypertension in Europe investigators. The prevention of dementia with antihypertensive treatment. Arch Int Med 2002; 162: 2046-2052.
18. Mason R, Leeds P, Jacob R, Hough C, Zhang K, Mason P, et al. Inhibition of excessive neuronal apoptosis by the calcium antagonist amlodipine and antioxidents in cerebellar granule cells. J Neurochem 1999; 72:1448-1456.
19. Tomassioni D, Lanari A, Silvestrelli G, Traini E, Amenta F. Nimodipine and its use in cerebrovascular disease: evidence from recent preclinical and controlled clinical trials. Clin Exp Hypertens 2008; 30:744-766.
20. Trompet S, Westendorp R, Kamper A, Craen A. Use of calcium antagonists and cognitive decline in old age. The Leiden 85-plus study. Neurobiol Aging 2008; 29:306-308.
21. Paran E, Anson O, Lowenthal D. Cognitive functioning and antihypertensive treatment in the elderly: a 6-year follow-up study. Am J Ther 2010; 17:358-364.
22. Maxwell C, Hogan D, Ebly E. Calcium-channel blockers and cognitive function in elderly people: results from the Canadian study of health and aging. CMAJ 1999; 161:501-506.
23. Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield M, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009; 27:2121-2158.
24. Dasgupta K, Quinn R, Zamke K, Rabi D, Ravani P, Daskalopoulou S, et al. The 2014 Canadian hypertension education rrogram recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol 2014; 30:485-501.
25. Ogihara T, Kikuchi K, Matsuoka H, Fujita T, Higaki J, Horiuchi M, et al., The Japanese Society of Hypertension Committee. The Japanese society of hypertension guidelines for the management of hypertension (JSH 2009). Hypertens Res 2009; 32:3-107.
26. Chiang C, Wang T, Li Y, Lin T, Chien K, Yeh H, et al. 2010 guidelines of the Taiwan Society of Cardiology for the management of hypertension. J Formos Med Assoc 2010; 109:740-773.
27. Liu L. 2010 Chinese guidelines for the management of hypertension. Chin J Cardiol 2011; 39:579-616.
28. Sanchez R, Ayala M, Baglivo H, Velazquez C, Burlando G, Kohlmann O, et al. Latin American guidelines on hypertension. Hypertens 2009; 27:905-922.
29. Seedat Y, Rayner B. South African Hypertension Guideline 2011. S Afr Med 2012; 102:57-84.
30. American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents, American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, European Society of Hypertension. ACCF/AHA 2011 expert consensus document on hypertension in the elderly. J Am Coll Cardiol 2011; 57:2037-2114.
31. Hypertension Clinical management of primary hypertension in adults. National Institute of Health and Clinical Excellence. UK. http:// www.nice.org.uk/nicemedia/live/13561/56008.pdf. [Accessed 20 June 2014]
32. National Institute for Health and Clinical Excellence. Consultation on potential new indicators for the 2013/14 Quality and Outcomes Framework (QOF). http://www.nice.org.uk/aboutnice/qof/indicators-detail. jsp?summary=13812. [Accessed 19 June 2014]
33. McGuinness B, Todd S, Passmore P, Bullock R. Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia. Cochrane Database Syst Rev 2009;CD004034.
34. Chen N, Zhou M, Yang M, Guo J, Zhu C, Yang J, et al. Calcium channel blockers versus other classes of drugs for hypertension. Cochrane Database Syst Rev 2010;CD003654.
35. Critical Appraisal Skills Program. http://www.casp-uk.net/. [Accessed 20 June 2014]
36. Higgins J, Altman D, Gøtzsche P, Jüni P, Moher D, Oxman A, et al. Cochrane Bias Methods Group, Cochrane Statistical Methods Group. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011; 343:d5928.
37. Khactaturian A, Zandi P, Lyketsos C, Hayden K, Skoog I, Norton M, et al. Antihypertensive medication use and incident Alzheimer disease. Arch Neurol 2006; 63:686-692.
38. Yasar S, Corrada M, Brookmeyer R, Kawas C. Calcium channel blockers and risk of AD: the Baltimore Longitudinal Study of Aging. Neurobiol Aging 2005; 26:157-163.
39. Haag M, Hofman A, Koudstaal P, Breteler M, Stricker B. Duration of antihypertensive drug us and risk of dementia. Neurol 2009; 72:1727-1734.
40. Murray M, Lane K, Gao S, Evans R, Unverzagt F, Hall K, et al. Preservation of cognitive function with antihypertensive medications. Arch Int Med 2002; 162:2090-2096.
41. Yasar S, Xia J, Yao W, Furberg C, Xue Q, Mercado C, et al. Antihypertensive drugs decrease risk of Alzheimer's disease: Ginkgo Evaluation on Memory Study. Neurol 2013; 81:896-903.
42. Gelber R, Ross G, Petrovitch H, Masaki K, Launer L, White L. Antihypertensive medication use and risk of cognitive impairment. The Honolulu-Asia Aging Study. Neurol 2013; 81:1-8.
43. Ogihara T, Kuramoto K. On behalf of the NICS-EH Study Group. Effect of long-term treatment with antihypertensive drugs on quality of life of elderly patients with hypertension: a double-blind comparative study between a calcium antagonist and a diuretic. Hypertens Res 2000; 23:33-37.
44. Schrader J, Lüders S, Kulschewski A, Hammersen F, Plate K, Berger J, et al. Morbidity and mortality after stroke, eprosartin compared with nitrendipine for secondary prevention: principal results of a prospective randomised controlled study. Stroke 2005; 36:1218-1224.
45. Hajar I, Catoe H, Sixta S, Boland R, Johnson D, Hirth V, et al. Crosssectional and longitudinal association between antihypertensive medications and cognitive impairment in an elderly population. J Gerontol Med Sci 2005; 60A:67-73.
46. Sato N, Saijo Y, Sasagawa Y, Morimoto H, Takeuchi T, Sano H, et al. Combination of antihypertensive therapy in the elderly, multicenter investigation (CAMUI) trial: results after 1 year. J Hypertens 2013; 31:1245-1255.
47. Watfa G, Rossignol P, Kearney-Schwartz A, Renaud F, Bracard S, Felblinger J, et al. Use of calcium channel blockers is associated with better cognitive performance in older hypertensive patients with subjective memory complaints. J Hypertens 2010; 28:2485-2493.
48. Louis E, Benito-León J, Bermejo-Pareja F. on behalf of the Neurological Disorders in Central Spain (NEDICES) study group. Antihypertensive agents and risk of Parkinson's disease, essential tremor and dementia: a population-based prospective study (NEDICES). Neuroepidemiology 2009; 33:286-292.
49. The PROGRESS Collaborative Group. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med 2003; 163:1069-1075.
50. Birks J, López-Arrieta J. Nimodipine for primary degenerative, mixed and vascular dementia. Cochrane Database Syst Rev 2002;CD000147.
51. Paris D, Bachmeier C, Patel N, Quadros A, Volmar C, Laporte V, et al. Selective antihypertensive dihydropyridines lower Aß accumulation by targeting both the production and the clearance of Aß across the bloodbrain barrier. Mol Med 2011; 17:149-162.
52. Nimmrich V, Eckert A. Calcium channel blockers and dementia. Br J Pharmacol 2013; 169:1203-1210.
53. Hainsworth A, McNaughton N, Pereverzev A, Schneider T, Randall A. Actions of sipatrigine, 202W92 and lamotrigine on R-type and T-type Ca2 channel currents. Eur J Pharmacol 2003; 467:77-80.
54. Hainsworth A, Stefani A, Calabresi P, Smith T, Leach M. Sipatrigine (BW 619C89) is a neuroprotective agent and a sodium channel and calcium channel inhibitor. CNS Drug Rev 2000; 6:111-134.
55. Stefani A, Hainsworth A. Gabapentin-mediated effects on voltage-and ligand-gated currents. Curr Neuropharmacol 2003; 1:237-244.